The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 10, 2024

Filed:

Dec. 07, 2018
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Kedar Himanshu Dave, Seattle, WA (US);

Todd Devries, Seattle, WA (US);

Ronald James Hause, Jr., Seattle, WA (US);

Ryan P. Larson, Seattle, WA (US);

Christopher Glen Ramsborg, Seattle, WA (US);

Claire L. Sutherland, Seattle, WA (US);

Nathan K. Yee, Seattle, CA (US);

Rachel K. Yost, Seattle, WA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/85 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); C12N 15/85 (2013.01); G01N 33/5091 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2500/90 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01);
Abstract

Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.


Find Patent Forward Citations

Loading…